Idiopathic nephrotic syndrome and rituximab: may we predict circulating B lymphocytes recovery?
Delbet, Jean Daniel; Leclerc, Gael; Ulinski, Tim.
; 34(3): 529-532, 2019 03.
Artigo em Inglês | MEDLINE | ID: mdl-30542932
Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome.
Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome.
It's Hard to Teach an Old B Cell New Tricks.
How to improve response to rituximab treatment in children with steroid-dependent nephrotic syndrome: answer to Drs. Fujinaga and Nishino.
Relapse of nephrotic syndrome during post-rituximab peripheral blood B-lymphocyte depletion.
Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis.
Novel use of rituximab for steroid-dependent nephrotic syndrome in children.
Trafficking of B cell antigen in lymph nodes.
Response to "Predictors of rituximab-related neutropenia in Japanese children with steroid-dependent nephrotic syndrome".
Predictors of rituximab-related neutropenia in Japanese children with steroid-dependent nephrotic syndrome.